La Chine approuve une série d'appareils de "télépathie" dans le but de dépasser Elon Musk

China's health regulators have approved several brain-technology products this year, marking a significant step in the nation's efforts to establish itself as a leader in brain-computer interface (BCI) innovation. The move comes amid a broader strategy to challenge international competitors, including Elon Musk's Neuralink, and to advance treatments for neurological disorders such as paraplegia, Alzheimer’s, and depression. The approvals were announced by China’s National Medical Products Administration (NMPA), which granted clearance to multiple devices designed to interpret brain activity. One notable product is a system developed by Tiankai Suishi (Tianjin) Intelligent Technology, a domestic firm that has gained attention for its innovative approach to cognitive assessment. This device features a cap equipped with electrodes that measure electrical signals emitted by the brain, enabling healthcare professionals to evaluate potential impairments in cognitive function. According to the company’s official WeChat feed, the device was approved by the NMPA on August 19. The technology allows for non-invasive monitoring of neural activity, potentially aiding in the early detection of conditions like Alzheimer’s disease and schizophrenia. Tiankai Suishi also offers other BCI devices aimed at identifying early signs of cognitive dysfunction. The company is currently pursuing regulatory approval for a new product focused on diagnosing depression, further expanding its portfolio in the field. Founded in 2023, Tiankai Suishi has secured a registered capital of 10.67 million yuan (approximately US$1.59 million). The company is led by Gu Bin, who holds a doctoral degree from Tianjin University’s medical school, as reported by Chinese media. His academic background underscores the firm’s commitment to scientific rigor and technological advancement. The expansion of the BCI sector in China reflects a growing emphasis on health-tech innovation driven by demographic shifts. As the population ages rapidly, there is an increasing demand for advanced diagnostic tools and therapeutic interventions. Local governments have played a crucial role in fostering this growth, providing financial incentives and creating supportive environments for startups. Private investment in the sector has surged, reflecting confidence in the long-term potential of brain-computer interface technologies. This trend aligns with broader national goals to position China at the forefront of emerging technologies. By supporting domestic companies, the government aims to reduce reliance on foreign innovations and promote self-reliance in critical areas of healthcare. The regulatory approvals signal a willingness to accelerate the commercialization of these technologies, ensuring they reach patients more quickly. As the sector continues to evolve, the focus will likely shift toward refining existing technologies and developing new applications. Companies like Tiankai Suishi are expected to play a pivotal role in shaping the future of neurotechnology in China. With ongoing research and regulatory support, the path forward promises both challenges and opportunities for innovation in the realm of brain-computing interfaces.